The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy,” published in the December 2024 issue of Oncology by Pujari et al.
De novo oligometastatic breast cancer (dOMBC) involves multiple metastatic sites, which may be treated with curative intent using surgery and radiotherapy.
Researchers conducted a retrospective study analyzing the outcomes of dOMBC treated with curative intent.
They collected data from a database using electronic medical records and the Radiation Oncology Information System (ROIS), dOMBC was defined as having up to 3 metastatic sites treatable with ablative radiotherapy (RT), and both primary and axillary diseases amenable to curative surgery, patients received surgery, systemic therapy (ST), and RT.
The results showed that patients underwent breast-conserving surgery or modified radical mastectomy and received 6 to 8 cycles of chemotherapy in the neoadjuvant and/or adjuvant setting. Hormone receptor-positive patients were treated with tamoxifen or aromatase inhibitors, while patients with human epidermal growth factor receptor 2 (HER-2) received positive trastuzumab. The RT included locoregional RT and metastasis-directed ablative body RT. The median progression-free survival (PFS) was 39 months (95% CI: −28.7 to 50.1 months). The 2- and 3-year estimated disease-free survival (DFS) rates were 79% and 60.5%, respectively. The median OS was not reached, and the estimated 3-year OS was 87.3%. Total lesional glycolysis (TLG) of metastases and p53 status did not affect DFS.
They concluded that a combination of surgery, metastasis-directed ablative RT, and ST may improve DFS in dOMBC.
